Your AI-Trained Oncology Knowledge Connection!
Robert Wenham, MD, MS, FACOG, FACS, discusses the current treatment landscape for patients with cervical and endometrial cancers, ADCs and PARP inhibitors in ovarian cancer, advancements in HER2-positive breast cancer, and surgical options for patients with ovarian cancer.
Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.
The European Commission has approved pembrolizumab for adjuvant treatment of adult and adolescent patients 12 years and older with stage IIB or IIC melanoma who have undergone a complete resection.
Florida Cancer Specialists & Research Institute clinicians and leaders shared the latest advances in oncology pharmacy operations and dispensing practices at the National Community Oncology Dispensing Association 2022 Spring Forum held last month in Atlanta.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization for asciminib for the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who were previously treated with at least 2 TKIs.
The CAR T-cell therapy ciltacabtagene autoleucel generated a high response rate in patients with multiple myeloma who experienced early clinical relapse or failure to initial therapy.
Treatment with the combination of cobolimab and dostarlimab led to an overall objective response rate and immune-related ORR of 42.9% consisting of all partial responses in patients with advanced or metastatic melanoma.
Sikander Ailawadhi, MD, discusses early efficacy observed with iopofosine I-131, the rationale of investigating the agent in the CLOVER WaM trial in patients with Waldenström macroglobulinemia, and how the radiotherapeutic could affect the treatment paradigm.
Tian Zhang, MD, discusses the benefits of multidisciplinary collaboration, how to select the best agents for each patient, and how treatments such as radiation in RCC and bladder-sparing chemoradiation in urothelial cancer fit into the overall treatment paradigms for these diseases.
The European Medicines Agency's Committee for Medicinal Products for Human Use has unanimously recommended full marketing authorization approval of melphalan flufenamide for patients with triple-class refractory multiple myeloma.
A new drug application has been submitted to the FDA seeking the approval of elacestrant in the treatment of patients with estrogen receptor–positive, HER2-negative, advanced or metastatic breast cancer.
Eunice Wang, MD, discusses the long-term results of a phase 2 trial investigating crenolanib plus chemotherapy in adult patients with newly diagnosed FLT3-mutant acute myeloid leukemia.
HPN328, a novel half-life extended DLL3-targeting T-cell engager, demonstrated clinical activity and tolerability in patients with pretreated small cell lung cancer and other neuroendocrine tumors, according to findings from a phase 1/2 study (NCT04471727).
Sylvester Comprehensive Cancer Center is making another bold move to accelerate cancer research, celebrating the groundbreaking for a 244,000-square-foot, state-of-the-art Sylvester Comprehensive Cancer Center - Transformational Cancer Research Building.
“Compelling” data support the use of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer and the use of sacituzumab govitecan for patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.
The FDA has granted an accelerated approval to dabrafenib plus trametinib for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors harboring a BRAF V600E mutation who have progressed following previous treatment and who have no satisfactory alternative treatment options.
The FDA has granted an orphan drug designation to VBI-1901, a novel cancer immunotherapeutic vaccine candidate, as a potential therapeutic option for patients with glioblastoma.
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency accepted for review the marketing authorization application for aumolertinib for the first-line treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with activating EGFR mutations and locally advanced/metastatic EGFR T790M mutation–positive non–small cell lung cancer.
The FDA has granted an orphan drug designation to the CD20-targeted autologous CAR T-cell therapy, MB-106, for use as a potential therapeutic option in patients with Waldenström macroglobulinemia.
The US Preventive Services Task Force updated its lung cancer screening guidelines in 2021 to include more members of vulnerable populations, including African Americans, women, and the LGBTQ community.
The European Medicines Agency has validated a Type II Variation application for trastuzumab deruxtecan as monotherapy for adults with unresectable or metastatic HER2-low breast cancer.
The European Commission has approved capmatinib as a single agent for the treatment of patients with MET exon14 skipping–altered advanced non–small cell lung cancer who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Allegheny Health Network Cancer Institute and Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling to enhance patient care.
Monique Minnema, MD, discusses the rationale of the MonumenTAL-1 trial examining talquetamab in multiple myeloma, the safety and efficacy reported thus far with the bispecific antibody, and next steps for further exploration.
Suneel Kamath, MD, discusses the findings from research he conducted evaluating the effect of financial and racial disparities on cancer incidence and mortality.
Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.
Guadecitabine did not result in a statistically significant improvement in overall survival compared with physician’s choice of treatment in patients with relapsed/refractory myelodysplastic syndrome or chronic myelomonocytic leukemia, according to data from the phase 3 ASTRAL-3 trial.
The FDA has granted an orphan drug designation to PT217 for use as a potential therapeutic option for patients with small cell lung cancer.
Florida Cancer Specialists & Research Institute, LLC has opened a new state-of-the-art facility at 8981 Colonial Center Drive in Fort Myers to provide comprehensive treatments and a variety of services to adults with cancer and other diseases.
